Conclusions TEACH is an effective intervention among patients with CD to improve patient activation and QOL, even among a cohort with GFD adherence at baseline. (J Pediatr 2017;185:62-7).
Trial registration ClinicalTrials.gov: NCT02458898.
C eliac disease (CD) is an immune-mediated enteropathy caused by gluten ingestion that results in increased intestinal permeability and nutrient malabsorption. There are nearly 3 million people with CD in the US, the majority of whom are undiagnosed or untreated, with an estimated prevalence of 3-13:1000 among the pediatric population. [1] [2] [3] [4] Uncontrolled CD can lead to poor quality of life (QOL) and morbidity, including infertility, nontraumatic fractures, and malignancy. [1] [2] [3] [4] The only treatment for CD at this time is strict elimination of gluten from the diet.
Although the management of CD is simple in theory, lifelong adherence to a gluten-free diet (GFD) can be challenging. The adolescent and young adult population is at increased risk for poor adherence in the management of chronic illnesses. [5] [6] [7] Barriers to adherence identified among patients with chronic disease include a desire for normality and freedom, poor physical or mental well-being, and lack of support from peers, parents, or healthcare providers. 6 Adolescents with CD are more likely to be nonadherent to GFD compared with younger children or adults, particularly in social settings outside the home or when transitioning to college where they have greater independence in preparing meals and are more susceptible to peer pressure. [8] [9] [10] [11] Patients with nonadherence in the management of chronic disease are at risk for poor QOL, adverse health outcomes, and increased healthcare costs. 7, 12 Studies among adults with CD show improvement in GFD adherence using online behavioral interventions, 13 yet there is a paucity of research among the adolescent population with CD to address GFD adherence. Growing evidence suggests that patients with chronic disease may adopt health-conscious comanagement skills through online behavioral intervention or mobile technology such as text messaging. [14] [15] [16] [17] Text messaging is a familiar form of communication among adolescents; 91% of teens with a cell phone use text messaging to communicate with an average of 30 messages sent and received per day. 18 Emerging adult [19] [20] [21] [22] [23] and pediatric [24] [25] [26] [27] [28] [29] [30] [31] data from the current self-monitoring mobile health movement show that welldesigned phone text messaging interventions reduce adverse health outcomes, improve adherence to therapy plans, increase patient activation, and improve overall QOL among patients with chronic disease. However, there are no studies showing similar utility of text messaging among adolescents or young adults with CD.
We hypothesize that our Text Message Educational Automated Compliance Help (TEACH) program may be a novel text message intervention to engage and educate adolescents and young adults with CD. Intended as an automated text messaging tool, we designed the components of TEACH to be a pragmatic way to improve GFD adherence, patient activation, and QOL among adolescents and young adults with CD. The primary objective of this study was to determine whether enrollment in TEACH will improve GFD adherence as measured by percent change in serum tissue transglutaminase (TTG) IgA and deamidated gliadin peptide (DGP) IgA over the 3-month study period. The secondary objective was to determine TEACH's impact on patientreported GFD adherence, patient activation, disease symptomatology, and QOL.
Methods
The TEACH Program study (ClinicalTrials.gov: NCT02458898) is a block randomized controlled clinical trial among 61 patients ages 12-24 years with CD. The study protocol and ethical considerations were approved by the Stanford Human Subjects Research and Institutional Review Board. Informed telephone consent was obtained from parents for children <18 years of age with online assent or consent provided by study participants depending on age. Participant referral, consent, and data collection were performed through an integrated, secure Stanford Research Electronic Data Capture (REDCap) database. After obtaining consent and child assent when indicated, participants were randomized into the TEACH intervention group receiving text messages or the control group with standard of care management by their primary gastroenterologist. The control group was aware of their enrollment in a text message reminder study through the informed consent process. All participants completed 4 surveys including the Celiac Dietary Adherence Test (CDAT), National Institutes of Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) Global Short Form, Celiac Symptom Index (CSI), and Patient Activation Measure (PAM) online through the secure REDCap database upon enrollment and after completion of the 3-month study intervention period. Serum TTG IgA and DGP IgA were obtained at the time of enrollment and after the 3-month study intervention through Stanford or LabCorp laboratory. Total IgA levels were obtained with enrollment laboratories to evaluate for IgA deficiency.
Participants were referred from Stanford Children's Health network, Oakland Children's Hospital, or through online social media recruitment from across the US using our REDCap patient referral website and were screened for eligibility by the principle investigator over the phone. Enrollment criteria included age 12-24 years, CD diagnosed at least 1 year prior to study enrollment, access to a mobile phone and email, and the ability to read English. Sixty-one participants were enrolled of 194 participant referrals (Figure 1 ; available at www.jpeds.com).
Block randomization was performed based on enrollment TTG IgA level (<4, 4-10, or >10). Randomization algorithm was generated by coin flip and was integrated into the REDCap database programming to occur once consent and baseline outcome measures were obtained by study coordinator.
TEACH intervention was comprised of 45 unique messages developed by our study team and CD dietician ( Table I ; available at www.jpeds.com). Automated text messages were sent to the TEACH intervention cohort 2-3 times per week in the evenings over the 3-month study period via Twilio interface with REDCap study website. Text message content included 15 links to online resources such as gluten-free recipes, restaurant search tools, or CD organization websites, 15 humorous reminders to stay gluten-free, and 15 bidirectional quiz questions. A complete list of text messages sent to participants is shown in Table I .
Demographic information was obtained upon enrollment (Table II) . Participants completed 4 validated patientreported survey outcome measures (CDAT, NIH PROMIS Global Short Form, CSI, and PAM) at enrollment and after the 3-month study period. The CDAT is a measure of GFD adherence validated among adults, 32 though it has been used in a research setting among patients age 16 and above. 13 It is composed of 7 questions with scores ranging from 7 to 35; scores, <13 indicate good GFD adherence. 32 The NIH PROMIS Global Short Form is a 10-question measure of QOL validated among adults 18 years of age and above with physical and mental health components; higher scores indicate better QOL. 33 The CSI is a 16-question measure of CD activity validated among adults 18 years of age and above with scores ranging from 16 to 80; scores <30 indicate good disease control and scores >45 indicate poor disease control. 34 PAM is a 13-item measure of patient activation validated among adults age 18 years and above, though it has been used in a research setting among patients as young as 12 years of age. 35 Scores range from 0 to 100; higher scores indicate greater patient activation with an improvement by 4 points thought to be clinically meaningful. 36 Objective serum markers (TTG IgA and DGP IgA) were obtained at enrollment and after the 3-month study period through Stanford or LabCorp. The same laboratory system was used for enrollment and followup labs for each participant. Logs of text messages sent and participant responses were collected via REDCap study website, and anonymous participant feedback was obtained upon study completion.
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Statistical Analyses A 2-tailed paired Student t test was used to compare the percent change in TTG IgA and DGP IgA from enrollment with 3-month follow-up levels in the TEACH intervention group compared with the control group. The Wilcoxon signedrank test was also used to compare mean scores for patientreported survey outcomes at enrollment and upon study completion among the TEACH intervention group and the control group. Analysis followed intent-to-treat principles.
Results
Sixty-one participants were enrolled from March 2015 to November 2015, with data collection through February 2016; 30 participants were randomized to the control group and 31 participants to the TEACH group. As depicted in Figure 1 , all participants were analyzed in the group to which they were originally randomized; 1 participant from the TEACH group was lost to follow-up. The 5 participants who did not meet inclusion criteria had been diagnosed with CD for less than 1 year. Table II shows demographic information at the time of enrollment. Despite randomization there were more female participants in the control group. Of note, the majority of study participants were already adherent to a GFD at the time of enrollment based on TTG IgA levels, DGP IgA levels, and CDAT scores ( Table III) . The mean enrollment TTG IgA was 3.5 and 2.9 for the control and TEACH groups, respectively (normal <4); mean enrollment DGP IgA was 8.5 and 7.4, respectively (normal <10), and median enrollment CDAT scores 11.5 and 11, respectively (<13 indicates good adherence). Indeed, only 3 participants from the control group and 3 participants from the TEACH intervention group had an abnormal TTG IgA >4 at the time of enrollment.
Primary and Secondary Outcome Measures
Among the TEACH group, there was significant improvement comparing enrollment scores with 3-month follow-up scores in patient activation (PAM score 63.1 vs 72.5, P = .01) and QOL (NIH PROMIS Global Mental Health 50.8 vs 53.3, P = .01 and NIH PROMIS Global Physical Health 50.8 vs 57.7, P = .03) ( Table III, Figure 2, A) . No statistically significant differences were noted in any outcome measure among the control group (Table III, Figure 2, B) . There was no statistically significant difference in the percent change in TTG IgA or DGP IgA over the course of the study between the control group and the TEACH group (Table III) . However, 2 participants in the TEACH group with abnormal enrollment TTG IgA levels showed improvement after the 3-month study intervention.
Participants in the TEACH group demonstrated a mean bidirectional text message response rate of 81%. Overall, participants enjoyed the text message intervention; they felt the text messages reminded them to stay gluten-free and that the frequency of messages was appropriate (Table IV; available at www.jpeds.com).
Discussion
In this randomized controlled trial, we investigated the efficacy of a novel TEACH automated text messaging intervention in improving GFD adherence among adolescents and young adults with CD. Although a statistically significant change in TTG IgA and DGP IgA was not detected among our already adherent study population, we identified improvements in several secondary outcome measures among the TEACH intervention group. A statistically significant improvement in patient activation and QOL as measured by PAM and NIH PROMIS scores, respectively, over the course of the study was observed in the TEACH intervention group. It is important to note that these validated, patient-reported outcome measures increased even among a cohort of patients with baseline GFD adherence. This indicates that an automated text messaging platform for longitudinal patient education and activation such as TEACH benefits patients in optimizing wellbeing not readily captured by traditional markers of disease activity.
We selected 4 validated measures to assess patient-reported GFD adherence (CDAT), disease symptomatology (CSI), patient activation (PAM), and QOL (NIH PROMIS Global Short Form) as our secondary outcome measures. It should be noted that these measures have only been validated among patients 18 years of age and older. However, the CDAT and the PAM have been used in a pediatric setting in the literature, 13, 35 and the pediatric PROMIS global short form has 4 of the 7 questions identical to the general PROMIS global short form used in this study. 37 The PAM is a unique measure of patient activation that assesses a patient's ability for disease self-management, collaboration with healthcare providers, prevention of exacerbation, and access to care. 36 Increased levels of patient activation have been shown to improve quality and health outcomes among patients managing a chronic disease. 36, 38 Patient engagement and activation in self-management of a chronic illness such as CD is particularly important among the adolescent and young adult population who are transitioning outside the home and making independent dietary choices but is applicable to any patient struggling with a chronic disease. Lifelong management of CD with GFD is challenging given mealtime is often a shared, public interaction; a restrictive diet can cause social isolation and misunderstanding of CD. 39 This social isolation and high perceived health burden from lifelong GFD therapy among patients with CD can lead to depressive symptoms and negative QOL. 40, 41 Thus, a behavioral intervention such as TEACH that improves patient activation and QOL among patients with CD, even among a cohort of already adherent participants, is particularly important. Although we did not find the TEACH intervention to improve serum markers of GFD adherence, this may be due to the natural limitations of a pilot study with a smaller number of participants. We acknowledge a limitation of this study was the potential selection bias in patient recruitment leading to an already adherent population at the time of enrollment and likely dampening any measurable impact the TEACH program intervention may have on adherence. Studies among pediatric patients with CD indicate that TTG IgA and DGP IgA can decline as much as 60% over a 3-month period with GFD adherence; thus, we anticipated a measurable change was feasible in the study intervention period. 42 Though we attempted to recruit participants from a diverse array of geographic location and socioeconomic background, those participants who were willing to complete the surveys and laboratory draws were likely participants who were already following a GFD and TTG data omitted for 1 participant in the TEACH intervention group as labs were drawn after laboratory transitioned to a new form of testing with normal cut-off value <19 rather than <4.
Bold values indicate statistical significance (P < .05).
somewhat engaged with the long-term management of CD. It is unclear why there were significantly more female than male participants in the control group with our block randomization protocol; we anticipate this would become less impactful with a larger number of participants in future studies. There is also a possibility for a Hawthorne effect among the control group given their awareness of being observed during study enrollment through blood draws and surveys, which could minimize any differences in adherence that may have been present between the control group and intervention group over the course of the study. The study results are thought to be generalizable to the adolescent and young adult CD population given the diverse patient population recruited from across the US, and Pew study statistics indicating prevalence of text messaging in the adolescent population. 18 Mobile health interventions are a growing area of research to enact behavioral change among patients with chronic disease. Ultimately, our study shows that interactive text messages are a feasible, enjoyable intervention among the adolescent and young adult population with CD based on participant feedback (Table IV) . Future studies are needed to expand the bidirectional nature of text message interventions to promote more effective communication and personalization of reminders among patients with chronic disease. The TEACH program is a promising behavioral intervention to improve QOL and patient activation in self-management of chronic disease. We look forward to using the TEACH program in larger studies among a variety of chronic illnesses, and developing the interactive nature and personalization of text message content and frequency. ■ Online resources 27% Humorous reminders 37% Bidirectional quiz questions 37% (n = 30) Would you be interested in future studies with text messages over a longer period of time?
80% answered "yes" (n = 30)
Among the TEACH intervention group, the bidirectional text message response rate was 81% with 71% correct responses to the 15 quiz text message questions.
